WRN inhibitor 15 (Compound 9) is a WRN inhibitor with antitumor activity with IC50 of 37.9, 40.2, 46.6 μM in PC3, LNCaP, and HeLa, and can be used in prostate cancer research.

Physicochemical Properties

Molecular Formula	C16H13F2N3O
Molecular Weight	301.29
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References

[1]. Quinazoline derivatives inhibit cell growth of prostate cancer as a WRN helicase dependent manner by regulating DNA damage repair and microsatellite instability. Bioorg Chem. 2024 Dec:153:107963.

Solubility Data

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.3191 mL	16.5953 mL	33.1906 mL
	5 mM	0.6638 mL	3.3191 mL	6.6381 mL
	10 mM	0.3319 mL	1.6595 mL	3.3191 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.